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Introduction: Thirty years have gone by since the Masaoka staging
system of thymoma was proposed in 1981. Although the Masaoka
staging system has been accepted by many surgeons and patholo-
gists, some proposals of revision and improvements have been
suggested. At this time, I reinvestigated the Masaoka staging system
based on the recent follow-up study of the thymomas resected at
Nagoya City University.
Methods: Using the follow-up results of 211 thymomas in Nagoya,
I analyzed the following aspects: (1) evaluation of the Masaoka
staging system as a prognostic factor in the Nagoya series and (2)
critical assessment of the proposals of revision to the Masaoka
staging system.
Results: (1) Univariate analysis showed that Masaoka stages were
significantly prognostic for overall survival (p  0.0001). (2) The
difference of survivals between stage I and II was not significant, but
progression-free survival of stage I was 100% for up to 20 years,
whereas one tumor death case in stage II was found. (3) Differences
of survival between the cases with and without great vessel invasion
in stage III were not significant. (4) Prognosis of N tumors was yet
better defined.
Conclusion: (1) The Masaoka staging system remains a valuable
prognostic factor. (2) Combination of stage I with II and separation
of stage III into subgroups are not recommended. (3) At the moment,
it is better to include N tumors in stage IVb.
Key Words: Thymoma, Staging system, TNM classification, Fol-
low-up study.
(J Thorac Oncol. 2010;5: S304–S312)
In the 1960s, thymomas were classified into two categories:noninvasive and invasive. Bernatz et al.1 proposed a histo-
logic classification and described four histologic subtypes:
predominantly lymphocytic type, predominantly epithelial
type, predominantly mixed type, and predominantly spindle
cell type. Tumors belonging to the first three categories
consisted of round epithelial cells and lymphocytes with
differences in the ratio of the two components determining
the category that the tumor belonged to. Bernatz et al. found
that the predominantly epithelial subtype of thymoma was the
most dominant among invasive thymomas.
To quantify the ratio of epithelial cells and lympho-
cytes, we2 calculated the numbers of these cells and deter-
mined the lymphocytes to epithelial cells ratio (L/E ratio). In
our series of 22 cases, L/E ratios ranged from 0.27 to 4.10
with a mean value of 1.93 (Figure 1).
We also found a significant difference in the L/E ratios
of invasive and noninvasive thymomas (Figure 2) with inva-
sive thymomas having a lower ratio than noninvasive thymo-
mas. This had also been recognized by Bernatz et al. In our
series, we found three cases of recurrent thymoma with L/E
ratios that were strikingly lower as compared with tumors at
the time of diagnosis (Figure 3). Hence, it seemed that the
L/E ratio changed based on the biologic behavior of the
tumor: a decrease in the L/E ratio seemed to correlate with a
change in the nature of the tumor from encapsulated thy-
moma to invasive thymoma. This finding led to propose a
staging system for thymomas.
MASAOKA STAGING SYSTEM
To establish a new staging system for thymomas, we
took into consideration a few basic characteristics of the
disease:
1. Thymoma is a very slow growing tumor. In our expe-
rience, it could take as long as 30 years for a noninva-
sive thymoma to become invasive if it was not surgi-
cally resected.
2. Some noninvasive thymomas that had been resected
completely recurred in the same region.
3. Some patients with completely resected invasive thy-
momas could survive.
4. Pleural dissemination is a frequent site of progression.
5. Some patients develop lymphogenous or hematoge-
neous metastases.
Two other staging systems were developed by Bergh
et al.3 and Wilkins and Castleman4 (Table 1). The differ-
ence between the two systems was limited to one point:
stage II Wilkins thymoma involved pleura and pericardial
invasion.
In our opinion, there were some major inadequacies
in the staging systems of Bergh et al. and Wilkins and
Castleman: (1) the actual sites of intrathoracic metastasis
were not clear, (2) the description of invasion was inade-
quate, (3) stage III includes too broad spectrum of disease,
and (4) hematogenous and lymphogenous metastases were
not well represented.
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We proposed a surgical and pathologic staging system
based on the extent of disease in 1981 (Table 2).5 We defined
tumor extent as follows: (1) stage I: completely encapsulated,
(2) stage II: invasion by the second layer surrounding the
tumor (defined below), (3) stage III: direct invasion beyond
the second layer, and (4) discontinuous progression.
The anatomic layers surrounding the tumor are depicted
in Figure 4. Invasion into the pleural cavity is preceded by
breaching of anatomic barriers in the following sequence:
capsule, mediastinal pleura, visceral pleura, and finally lung.
On the other hand, when the tumor invades the mediastinum,
it invades through the capsule, mediastinal adipose tissue,
pericardium or great vessels, and finally heart. Accordingly,
the second layer surrounding the tumor is either the medias-
tinal pleura or mediastinal adipose tissue.
There are two points that need to be stressed. First,
stage II disease involves invasion into the mediastinal pleura
at perioperative inspection, even if histologic invasion could
not be proved. We believe that this finding precedes histo-
logic invasion.
Second, stage IV disease is divided into two categories
IVa and IVb. Stage IVa consists of serosal dissemination, i.e.,
involvement of the pleura and pericardium. Stage IVb con-
sists of metastasis via lymphogenous and hematogenous
routes. Accordingly, stage IVb includes cases with lymph
node metastasis at any station.
In 1981, we reviewed 93 thymoma cases at Osaka
University.5 The stage of disease is shown in Table 3. All
three cases of stage IVb disease had hematogenous metastasis
involving the liver, lung, and rib. Survival curves associated
with these four stages are shown in Figure 5.
CHANGE IN THE OPERATIVE PROCEDURE FOR
THYMOMA
In 1970s, an important problem for thoracic surgeons
was the operative route in thymectomy for myasthenia gravis.
Whether transsternal or transcervical, the target of resection
was the intracapsular thymus. I call it simple thymectomy.
However, we became aware that the results of transcer-
vical thymectomies were inferior to those of transsternal
thymectomies. We suspected that parts of the thymic tissues
might be left in the transcervical thymectomies. So, we
investigated the presence and distribution of thymic tissues in
the anterior mediastinum systematically.6 As a result of this
study, we found many foci of thymic tissues in the extrathy-
mic anterior mediastinal adipose tissues in most cases.
I thought that to eliminate the thymic tissues, en bloc
resection of the anterior mediastinal adipose tissues including
the thymus gland is necessary. So, I advocated to apply this
procedure in the treatment of myasthenia gravis, and named
it “extended thymectomy”.7 It could improve the operative
results for myasthenia gravis.
FIGURE 1. L/E ratio of thymomas. Reprinted with permis-
sion from Cancer 1977;40:1225.
FIGURE 2. L/E ratios of noninvasive and invasive thymo-
mas. Reprinted with permission from Cancer 1977;40:1226.
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On the other hand, at that time, another problem con-
cerning thymomectomy was pointed out. It was the occur-
rence of myasthenia gravis after thymomectomy for nonm-
yasthenic patients.8 In this era, resection of only the thymoma
was the standard operation for thymoma. I call it simple
thymomectomy. I thought, to prevent the occurrence of post-
thymomectomy myasthenia gravis, surgeons should perform
the extended thymectomy, instead of simple thymomectomy
for the thymoma patients, too.5
The aim of this procedure was prevention of the post-
thymomectomy myasthenia gravis, and its conduct in all
thymoma patients was supported by finding of lack of immu-
nologic deficiency in the myasthenic patients, who had un-
dergone these operations.
Table 4 shows transition of operative procedures in
Nagoya City University occurring every 5 years. In early
1980s, simple thymomectomy was dominant, but later the
extended thymectomies were performed in most patients.
After the extended thymectomy became a routine operation
for thymoma, we encountered lymphnode metastases, which
FIGURE 3. L/E ratios of initial and recurrent tumors in
three thymomas. Reprinted with permission from Cancer
1977;40:1227.
TABLE 1. Staging System by Bergh et al. and Wilkins and
Castleman3,4
Stage Description
Staging system by
Bergh et al.
Stage I Intact capsule or growth within the capsule
Stage II Pericapsular growth into the mediastinal fat tissue
Stage III Invasive growth into the surrounding organs,
intrathoracic metastases, or both
Staging system by
Wilkins and
Castleman
Stage I Intact capsule or growth within the capsule
Stage II Pericapsular growth into the mediastinal fat tissue
or adjacent pleura or pericardium
Stage III Invasive growth into the surrounding organs,
intrathoracic metastases, or both
TABLE 2. Masaoka Staging System5
Stage I Macroscopically completely encapsulated and microscopically
no capsular invasion
Stage II 1. Macroscopic invasion into surrounding fatty tissue or
mediastinal pleura, or
2. Microscopic invasion into capsule
Stage III Macroscopic invasion into neighboring organ, i.e., pericardium,
great vessels, or lung
Stage IVa Pleural or pericardial dissemination
Stage IVb Lymphogenous or hematogenous metastasis
Reprinted with permission from Cancer 1981;48:2485.
FIGURE 4. Process of invasion of thymoma. Left lane indi-
cates course to pleural cavity. Right lane indicates course to
deep mediastinum.
TABLE 3. Masaoka’s Stages and Patients Distribution
(Osaka University, 1981)
Stages No. of Patients
Stage I 37
Stage II 13
Stage III 32
Stage IVa 8
Stage IVb 3a
Total 93
a Liver, lung, and rib metastasis.
Masaoka Journal of Thoracic Oncology • Volume 5, Number 10, Supplement 4, October 2010
Copyright © 2010 by the International Association for the Study of Lung CancerS306
were found in the anterior mediastinal adipose tissues re-
sected by this operation. This let us propose our tumor, node,
metastasis (TNM) classification system.
TNM CLASSIFICATION SYSTEM
In 1991, we proposed a TNM classification system for
thymoma (Table 5).9 T factors mimicked the staging criteria.
N1 corresponds to anterior mediastinal, N2 other mediastinal,
and N3 extrathoracic lymphnode metastasis. M1 means he-
matogenous metastasis in any organ.
However, the staging system was not revised. All
N-positive and M-positive cases were included in stage
IVb.
EVALUATION OF THE MASAOKA STAGING
SYSTEM AS A PROGNOSTIC FACTOR
Many authors investigated the relationship between the
Masaoka stage and survival. Major articles on these investi-
gations since 1990 are listed in Table 6.10–26 Almost all
authors except Wilkins et al.13 recognized a significant cor-
relation between staging and survival.
REINVESTIGATION OF THE MASAOKA
STAGING SYSTEM
In 1980, I was transferred to Nagoya City University
from Osaka University. In 2010, we performed a follow-up
study of thymomas in Nagoya City University and reinves-
tigated the relationship between stages and survival after an
interval of 30 years from the Osaka series.27
The series consists of 211 thymomas treated in Nagoya
City University Hospital from 1971 to 2008. Of these, 201
patients underwent operations: exploratory thoracotomy in 7,
subtotal resection of tumor in 30, simple thymomectomy in
33, and extended thymectomy in 131 patients. Stage distri-
bution is as follows: stage I 76 (36.0%), stage II 61 (28.9%),
stage III 31 (14.7%), stage IVa 33 (15.6%), and stage IVb 10
(4.7%). Two survival parameters were adopted: overall sur-
vival and progression-free survival.
The overall survivals of each stage are shown in Figure 6
and Table 7. The curves are arranged stepwise according to the
stages. Survival of IVb seems somewhat superior to that of IVa.
Significant differences are found in I versus III, I versus IVa, I
versus IVb, II versus III, II versus IVa, II versus IVb.
The progression-free survivals are shown in Figure 7
and Table 8. The survival curves of I and II become much
closer and have high percentage of survival (stage I: 100%,
stage II: 94.1%). The survival curves of stage IVa and IVb
are nearly superimposed. Overall survival curves seem to
fall into three groups; stage I and II, stage III, and stage
IVa and IVb.
The reason why the progression-free survival rates of
stage I and II lie higher than the overall survival curves is that
most of the deaths in stage I and II are due to the associated
disease or complication of therapies, but not the tumor.
Indeed, only one patient with stage II died due to tumor
recurrence. In contrast, the progression-free survival rates of
stage IVb were lower than the overall survival rates. This
FIGURE 5. Survival curves of each stage in thymoma
(Osaka University, 1981). Reprinted with permission from
Cancer 1981;48:2491.
TABLE 4. Transition of Operative Procedures
Exploratory
Thoracotomy
Subtotal
Resection
Simple
Thymomectomy
Extended
Thymectomy Total
1971–1975 1 0 1 0 2
1976–1980 1 0 5 2 8
1981–1985 1 2 8 6 17
1986–1990 2 3 6 9 20
1991–1995 0 3 1 19 23
1996–2000 0 8 0 22 30
2001–2005 0 8 3 43 54
2006–2008 2 6 9 30 47
Total 7 30 33 131 201
TABLE 5. TNM Classification of Thymoma (Yamakawa,
Masaoka)9
T factor
T1 Macroscopically completely encapsulated and microscopically
no capsular invasion
T2 Macroscopically adhesion or invasion into surrounding fatty
tissue or mediastinal pleura, or microscopic invasion
into capsule
T3 Invasion into neighboring organs, such as pericardium, great
vessels, and lung
T4 Pleural or pericardial dissemination
N factor
N0 No lymph node metastasis
N1 Metastasis to anterior mediastinal lymph nodes
N2 Metastasis to intrathoracic lymphnodes except anterior
mediastinal lymph nodes
N3 Metastasis to extrathoracic lymphnodes
M factor
M0 No hematogenous metastasis
M1 Hematogenous metastasis
Reprinted with permission from Cancer 1991;68:1986.
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finding was due to the presence of persistent tumor in sur-
viving patients with stage IVb.
Univariate analysis proved that the relationship be-
tween overall survival and stage is significant (p  0.0001).
However, we could not show a relation between progression-
free survival and stage, because the progression-free survival
in stage I remained 100% up to 20-year follow-up.
COMPARISON OF THE RESULTS OF THE
OSAKA SERIES AND THE NAGOYA SERIES
I compared the results of the Osaka series (n  93) and
the Nagoya series (n  211). Both were investigated with 30
years follow-up. Differences are as follows; (1) the overall
survivals in stage I and II of the Nagoya series are superior to
those of Osaka series (10-year survival rates of stage I: 87.1%
versus 66.7%, those of stage II: 80.6% versus 60.0%), (2) the
overall survivals in stage IV of Nagoya series are superior to
that of Osaka series (10-year survival rates of stage IV: IVa
20.0%, IVb 51.9% versus IV 0%).
These differences might be caused by the change in the
operative procedures. In the Osaka series, a majority of
patients underwent simple thymomectomies, whereas a ma-
jority of patients in the Nagoya series underwent extended
thymectomies. The extended thymectomies could reduce tu-
mor recurrence, particularly in stage I and II, and increase
incidence of N cases classified in stage IVb.
TABLE 6. The p Values of Stage vs. Survival
Author City Publish No. of Case Survival p Remarks
Pescarmona et al.10 Rome 1990 83 Overall 0.001
Regnard et al.11 Le Plessis- Robinson 1996 307 Disease free 0.00001
Gripp et al.12 Düsseldorf 1998 70 Disease free 0.0001
Wilkins et al.13 Baltimore 1999 136 Overall 0.123
Thymoma related 0.290
Lardinois et al.14 Lausanne 2000 71 Overall 0.05
Disease free 0.0001
Ogawa et al.15 Multi institutional 2002 103 Overall 0.0001
Disease free 0.0001
Okumura et al.16 Osaka 2002 273 Tumor specific 0.0001
Nakagawa et al.17 Tokyo 2003 130 Overall 0.000 Modified Masaoka
Kondo et al.18 Tokushima 2004 100 Disease free 0.002
Park et al.19 Seoul 2004 150 Overall 0.001 Thymic EP tumor
Rea et al.20 Padua 2004 132 Overall 0.003 Thymic EP tumor
Zhu et al.21 Shanghai 2004 175 Overall 0.0001
Disease free 0.0001
Kim et al.22 Seoul 2005 108 Tumor specific 0.000
Rena et al.23 Torino 2005 178 Overall 0.036
Disease free 0.012
Mineo et al.24 Rome 2005 88 Overall 0.001
Disease free 0.0001
Wright et al.25 Boston 2005 179 Tumor specific 0.0001 Thymic EP tumor
Bedini et al.26 Milan 2005 123 Progression free 0.0001
FIGURE 6. Masaoka stages and overall survival. Survival
curves are ranged stepwise. Survival curve of IVb seems
somewhat superior to that of IVa. I versus II: p  0.1162; I
versus III: p  0.0001; I versus IVa: p  0.0001; I versus IVb:
p  0.0001; II versus III: p  0.0094; II versus IVa: p 
0.0001; II versus IVb: p  0.0116; III versus IV: p  0.3319;
IVa versus IVb: p  0.7042.
TABLE 7. Masaoka Stage and Overall Survival
Survival Rate (%)/Patients at Risk
Postoperative Time (ys)
1 3 5 10 20
I/76 100/62 96.4/48 94.0/36 87.1/20 81.7/6
II/61 98.2/49 93.3/35 89.7/24 80.6/14 67.2/1
III/31 85.3/22 72.5/15 72.5/13 44.9/6 44.9/1
IVa/33 87.4/24 70.4/16 55.9/9 20.0/2
IVb/10 77.8/7 77.8/5 77.8/3 51.9/1
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Indeed, in the Osaka series, recurrences occurred in two
of 37 of stage I and three of 13 of stage II. On the other hand,
in the Nagoya series, recurrence occurred only in one of 61 of
stage II, who had undergone simple thymomectomy.
Furthermore, in the Nagoya series, nine N cases
were detected, whereas no N cases were observed in the
Osaka series. There were five cases of T3N1M0. Although
the mean follow-up period was only 4.3 years, two
T3N1M0 cases had recurrences. Prognosis of N thymoma
is a significant problem.
PROPOSALS OF REVISION OF THE MASAOKA
STAGING SYSTEM
Although the Masaoka staging system was in general
recognized as a valuable prognostic indicator, some proposals
for its revision have been suggested.
Combination of Stage I and II
Gupta et al.28 reviewed 21 papers published in the 21st
century and performed a metaanalysis of the results of stage
I and II cases. Because they did not find significant differ-
ences between them, they proposed to combine stage I and II,
and collapse the staging system into three stages.
I had read these 21 articles in detail and found two
issues that are important and need to be mentioned. The first
is divergence of the definition of stage II among reports.
Some include the cases with histologic invasion to mediasti-
nal pleura into stage II, whereas others include them into
stage III. Such confusion might originate from the insufficient
description of stage II that I wrote myself. The paragraph in
the definition of stage II 1 (Table 2) should be read as
follows: with or without histologic invasion.
The second issue to be mentioned is the lack of de-
scription of operative procedures in many of these 21 reports.
As mentioned earlier, the operative procedure might affect
the results. Whether extended thymectomy or simple thy-
momectomy was used is an important issue. However, many
authors did not describe it in their reports. The results of stage
I and II should be reinvestigated after addressing these two
issues.
Furthermore, there is a trend to use thoracoscopic
surgery for stage I and II thymoma, which does not allow to
perform an extended thymectomy. The prevalence of thora-
coscopic surgery could affect the survival of stage I and II
thymomas.
However, some reports recognized a significant differ-
ence between the results of stage I and II, as described by
Haniuda et al.,29 Mineo et al.,24 Maggi et al.,30 and Lardinois
et al.14
I did not observe significant differences between stage
I and II in overall survival. However, progression-free sur-
vival of stage I remained at 100% for a long time in our
series. In such circumstance, the presence of a tumor death
case in stage II might be meaningful, even if the number of
cases is very small.
Based on the above mentioned reasons, I think, it is
better to keep the separation of stage I and II at the moment.
Separation of Subgroups in Stage III
Okumura et al.31 suggested to divide stage III into two
subclasses, i.e., IIIa: without great vessel invasion and IIIb:
with great vessel invasion, based on his own data.
However, we did not find significant differences in
survival between the group with great vessel invasion and
that without great vessel invasion in our Nagoya series.
There are scarce reports concerning this subdivision.
Introduction of Other Factors Into the Staging
System
Asamura et al.32 proposed to add tumor size, based on
his own data, considering that large tumors (10 cm in
diameter) have a worse prognosis. However, tumor extent, as
proposed in the Masaoka staging system seems to be more
relevant than dimension. Furthermore, the fact that some
types of thymomas can be dramatically reduced in size
rapidly after administration of steroids argues against this
proposal for change.33
There have been proposals to include completeness of
operation in the staging system.11,34 Needless to say, com-
plete resection is the best prognostic factor. However, I think,
that a staging system should offer a guideline to select the
therapeutic modality. Completeness of resection could be
FIGURE 7. Masaoka stages and progression-free survival.
Those of stage IVa and IVb become nearly superimposed. I
versus any stage: not available; II versus III: p  0.0001; II
versus IVa: p  0.0001; II versus IVb: p  0.0001; III versus
IVa: p  0.1028; III versus IVb: p  0.7426; IVa versus IVb:
p  0.6021.
TABLE 8. Masaoka Stage and Progression-Free Survival
Survival Rate (%)/Patients at Risk
Postoperative Time (ys)
1 3 5 10 20
I/76 100/62 100/48 100/36 100/20 100/6
II/61 100/49 100/35 100/24 94.1/15 94.1/1
III/31 91.7/22 68.8/12 59.6/8 49.7/5 41.4/1
IVa/33 85.1/20 75.9/11 53.7/4 0/0
IVb/10 100/7 83.3/4 41.7/2 0/0
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designated by a separate parameter. I propose the following
criteria for results of surgery:
R0a  complete resection by extended thymectomy,
R0b  complete resection by simple thymomectomy,
R1  microscopically incomplete resection,
R2  macroscopically incomplete resection.
The subdivision of R0 cases should be useful to analyze the
results.
TNM CLASSIFICATION AND STAGE
In 2004, the World Health Organization (WHO) pro-
posed a system of TNM classification and staging (Table 9).35
This system is similar except for two points: (1) histologic
invasion into mediastinal pleura is categorized into T3, (2)
T1N1M0, T2N1M0, and T3N1M0 belong to stage III.
In 2005, Bedini et al.26 proposed a new system named
Istituto Nazionale Tumori TNM-based staging system (Table
10). I think, the system by Bedini et al. is too complicated and
limitation of the involved area by dissemination might cause
confusion in this staging system.
A major difference between the WHO system and mine
focuses on the allocation of N1. In the WHO staging system,
N1 is included in stage III, whereas it is included in stage IVb
in my classification. My system respects the concept of
invasion by contiguity (stage III) versus discontinuous pro-
gression (stage IV). On the contrary, the WHO staging
system respects localization of the involved area, giving
priority to the results of operation.
Staging systems of cancers of other organs use progres-
sion of metastasis to lymphnode stations as an important part
of stage definition. However, lymphnode metastasis is a rare
situation in thymoma, and its progression stages are poorly
defined. Kondo and Monden36 collected follow-up data of
1064 thymomas in Japan and there were only 19 (1.8%) cases
of N thymomas. This is a low incidence compared with the
cancers of other organs. Also in our series, the incidence of
N tumor was low: nine of 211 (4.3%). The behavior of
lymphogenous metastasis of thymoma warrants further inves-
tigation. Until more information is obtained, it might be better
to include the N thymomas in IVb stage.
EPILOGUE
The Masaoka staging system still remains a valuable
and reproducible prognostic factor of thymoma. However,
some proposals of revision of the staging system have been
offered, to identify significant differences in survival between
each identified stage. In my opinion, the staging system
should obey the following principles:
1. It should be logically justified.
2. It should be simple to use.
3. Frequent revisions should be avoided.
TABLE 9. WHO Staging System: TNM Classification
T-Primary tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor completely encapsulated
T2 Tumor invades pericapsular connective tissue
T3 Tumor invades into neighboring structures, such as pericardium, mediastinal pleura,
thoracic wall, great vessels, and lung
T4 Tumor with pleural or pericardial dissemination
N-Regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in anterior mediastinal lymph nodes
N2 Metastasis in other intrathoracic lymph nodes excluding anterior mediastinal lymph nodes
N3 Metastasis in scalene and/or supraclavicular lymph nodes
M-Distant metastasis
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
Stage grouping
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T1 N1 M0
T2 N1 M0
T3 N0, 1 M0
Stage IV T4 Any N M0
Any T N2, 3 M0
Any T Any N M1
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Since modalities of diagnosis and treatment are progressing
day by day, a staging system should be as comprehensive as
yet as simple as possible.
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